Predictive value of microsatellite instability-high remains controversial [7]

Journal of Clinical Oncology

Volumn 25, Issue 30, 2007, Pages 4857-

  Kim, George P ^a   Colangelo, Linda H ^a   Paik, Soonmyung ^a   O'Connell, Michael J ^a   Kirsch, Ilan R ^a   Allegra, Carmen ^a   Wolmark, Norman ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; MICROSATELLITE DNA;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL STUDY; COLON CANCER; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PATIENT SELECTION; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; DRUG RESISTANCE; GENETICS; GENOMIC INSTABILITY; NEOPLASM; NOTE;

DRUG RESISTANCE, NEOPLASM; GENOMIC INSTABILITY; HUMANS; MICROSATELLITE REPEATS; NEOPLASMS; PROGNOSIS;

EID: 36048960108     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.2019     Document Type: Letter

References (3)

1. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
2. Zdraveski ZZ, Mello JA, Farinelli CK, et al: MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 277:1255-1260, 2002
3. Bertagnolli MM, Compton CC, Niedzwiecki D, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol 24:541s, 2006 (abstr 10003)